AFP（或任何生物标志物）是否应用于HCC监测？

StephenW

Current Hepatology Reports

June 2017, Volume 16, Issue 2, pp 137–145
Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

    Authors
    Authors and affiliations

    Hager F. Ahmed Mohammed  Lewis R. Roberts Email author

    Hager F. Ahmed Mohammed
        12
    Lewis R. Roberts
        1Email author

    1.Division of Gastroenterology and HepatologyMayo Clinic College of Medicine and ScienceRochesterUSA
    2.Department of PediatricsUniversity of MinnesotaMinneapolisUSA

Hepatic Cancer (A Singal and A Mufti, Section Editors)

First Online:
    28 April 2017

DOI: 10.1007/s11901-017-0349-7

Cite this article as:
    Ahmed Mohammed, H.F. & Roberts, L.R. Curr Hepatology Rep (2017) 16: 137. doi:10.1007/s11901-017-0349-7

  

Abstract
Purpose of Review

The aim of this review is to address the controversy around the use of biomarkers for hepatocellular carcinoma (HCC) surveillance in individuals with cirrhosis or chronic hepatitis B who are at risk for development of liver cancer.
Recent Findings

Recent studies suggest that surveillance for hepatocellular carcinoma is beneficial, even after adjustment for lead time and other biases. Alpha fetoprotein (AFP) is complementary to ultrasound (US) in surveillance, particularly in obese patients and patients with infiltrative tumors. US and AFP are both associated with harms to patients from false-positive overdiagnosis, with US appearing to cause greater harms. Including patient demographic characteristics and additional biomarkers into diagnostic models is beneficial. Recent studies emphasize the advantage of time trends in biomarkers over single cross-sectional measurements.
Summary

AFP and other biomarkers are complementary to US in surveillance for HCC, especially when applied in models including patient variables and incorporating time trends in biomarker levels. With advances in genetic and molecular analysis of tumors, we may be poised at the cusp of a revolution in HCC surveillance.
Keywords
Des-gamma carboxy prothrombin AFP-L3 GALAD Liver cancer Hepatocellular carcinoma Screening Cirrhosis

StephenW

当前肝病学报告

2017年6月，第16卷，第2期，第137-145页
AFP（或任何生物标志物）是否应用于HCC监测？

    作者
    作者和附属机构

    Hager F. Ahmed Mohammed Lewis R. Roberts电子邮件作者

    哈格·艾哈迈德·穆罕默德
        12
    刘易斯·罗伯茨
        1电子邮件作者

    胃肠病学与肝病学分科医学与科学学院兽医学院
    明尼苏达州明尼阿波利斯大学儿科学系

肝癌（A Singal and A Mufti，Section Editors）

首先在线：
    2017年4月28日

DOI：10.1007 / s11901-017-0349-7

引用本文：
    Ahmed Mohammed，H.F.＆Roberts，L.R。 Curr Hepatology Rep（2017）16：137. doi：10.1007 / s11901-017-0349-7

  

抽象
审查目的

这项审查的目的是解决在肝硬化或慢性乙型肝炎患者肝癌发病风险的肝细胞癌（HCC）监测中使用生物标志物的争议。
最近的调查结果

最近的研究表明，肝细胞癌的监测是有益的，即使在调整前期和其他偏倚之后。甲胎蛋白（AFP）在监测中与超声（US）互补，特别是在肥胖患者和浸润性肿瘤患者中。美国和法新社与假阳性过度诊断的患者都有危害，美国似乎造成更大的危害。将患者人口学特征和其他生物标志物纳入诊断模型是有益的。最近的研究强调了生物标志物的时间趋势比单个横断面测量的优势。
概要

法新社和其他生物标志物是对美国HCC监测的补充，特别是当应用于包括患者变量在内的模型并纳入生物标志物水平的时间趋势时。随着肿瘤的遗传和分子分析的进步，我们可能会在HCC监测革命的尖端。
关键词
Des-gamma羧基凝血酶原AFP-L3 GALAD肝癌肝细胞癌筛查肝硬化